Advanced

The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey.

Bocchetta, Martina; Galluzzi, Samantha; Kehoe, Patrick Gavin; Aguera, Eduardo; Bernabei, Roberto; Bullock, Roger; Ceccaldi, Mathieu; Dartigues, Jean-François; de Mendonça, Alexandre and Didic, Mira, et al. (2015) In Alzheimer's & Dementia 11(2). p.195-206
Abstract
We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of... (More)
We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Alzheimer's & Dementia
volume
11
issue
2
pages
195 - 206
publisher
Elsevier
external identifiers
  • pmid:25150733
  • wos:000351255100009
  • scopus:84929751761
ISSN
1552-5279
DOI
10.1016/j.jalz.2014.06.006
language
English
LU publication?
yes
id
e2a094ea-f228-451b-9a5f-e75bdbc7fd0b (old id 4614100)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25150733?dopt=Abstract
date added to LUP
2014-09-08 21:44:07
date last changed
2017-11-05 03:19:13
@article{e2a094ea-f228-451b-9a5f-e75bdbc7fd0b,
  abstract     = {We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P &lt; .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.},
  author       = {Bocchetta, Martina and Galluzzi, Samantha and Kehoe, Patrick Gavin and Aguera, Eduardo and Bernabei, Roberto and Bullock, Roger and Ceccaldi, Mathieu and Dartigues, Jean-François and de Mendonça, Alexandre and Didic, Mira and Eriksdotter, Maria and Félician, Olivier and Frölich, Lutz and Gertz, Hermann-Josef and Hallikainen, Merja and Hasselbalch, Steen G and Hausner, Lucrezia and Heuser, Isabell and Jessen, Frank and Jones, Roy W and Kurz, Alexander and Lawlor, Brian and Lleo, Alberto and Martinez-Lage, Pablo and Mecocci, Patrizia and Mehrabian, Shima and Monsch, Andreas and Nobili, Flavio and Nordberg, Agneta and Olde Rikkert, Marcel and Orgogozo, Jean-Marc and Pasquier, Florence and Peters, Oliver and Salmon, Eric and Sánchez-Castellano, Carmen and Santana, Isabel and Sarazin, Marie and Traykov, Latchezar and Tsolaki, Magda and Visser, Pieter Jelle and Wallin, Åsa and Wilcock, Gordon and Wilkinson, David and Wolf, Henrike and Yener, Görsev and Zekry, Dina and Frisoni, Giovanni B},
  issn         = {1552-5279},
  language     = {eng},
  number       = {2},
  pages        = {195--206},
  publisher    = {Elsevier},
  series       = {Alzheimer's & Dementia},
  title        = {The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey.},
  url          = {http://dx.doi.org/10.1016/j.jalz.2014.06.006},
  volume       = {11},
  year         = {2015},
}